Home › NDC Lookup › RxCUI directory › RxCUI 1598985

Atazanavir 50 MG Oral Powder — RxCUI 1598985

RxNorm drug concept · Semantic clinical drug
RxCUI 1598985 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1598985
Official nameAtazanavir 50 MG Oral Powder
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asatazanavir 50 MG (as atazanavir sulfate 56.9 MG) Oral Powder
FDA products mapped3
Package NDCs mapped3
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Atazanavir: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • This is one of the most common things people notice on atazanavir, and it happens to almost everyone who takes it. The medicine causes a buildup of a pigment called bilirubin in yo...
  • Why does my skin and the whites of my eyes look yellow since I started atazanavir?
  • Yes — this one really matters. Taking atazanavir with food can increase the amount your body absorbs by a significant margin, and it also keeps your blood levels more consistent th...
  • Do I really have to take this with food every single time?
📖 Read our full Atazanavir guide →

🕸️ Concept Web — How Atazanavir 50 MG Oral Powder Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Atazanavir 50 MG Oral Powder RxCUI 1598985

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Atazanavir 343047
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Reyataz 382467
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Atazanavir Oral Powder 1598984
    • Atazanavir Oral Powder Product 1598983
    • Atazanavir Oral Product 1154364
    • Atazanavir Oral Powder [Reyataz] 1598987
    • Reyataz Oral Powder Product 1598988
    • Reyataz Oral Product 1183050
    • Oral Powder 346289
    • Oral Powder Product 1294711
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Atazanavir 50 MG SCDC · 1598982
  • Atazanavir Oral Powder SCDF · 1598984
  • Atazanavir Oral Powder Product SCDG · 1598983
  • Atazanavir Oral Product SCDG · 1154364

Brand-Name Concepts

  • Atazanavir 50 MG Oral Powder [Reyataz] SBD · 1598989
  • Atazanavir 50 MG [Reyataz] SBDC · 1598986
  • Atazanavir Oral Powder [Reyataz] SBDF · 1598987
  • Reyataz Oral Powder Product SBDG · 1598988
  • Reyataz Oral Product SBDG · 1183050
  • Reyataz BN · 382467

📦 FDA Products & Package NDCs

3 products · 3 package NDCs
3 package NDCs map to RxCUI 1598985 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00003-3622-12 30 CAPSULE, GELATIN COATED in 1 BOTTLE, PLASTIC (0003-3622-1... REYATAZ E.R. Squibb & Sons, L.L.C. 2003-06-24
00003-3631-12 60 CAPSULE, GELATIN COATED in 1 BOTTLE, PLASTIC (0003-3631-1... REYATAZ E.R. Squibb & Sons, L.L.C. 2003-06-24
00003-3638-10 30 PACKET in 1 CARTON (0003-3638-10) / 1 POWDER in 1 PACKET REYATAZ E.R. Squibb & Sons, L.L.C. 2014-12-19
Observed labelers: E.R. Squibb & Sons, L.L.C. (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.